Provider fact sheet · dataset v2026.08.14-4 · last touched 2026-08-14
Ro: GLP-1 programs, prices, and verification status (2026)
Ro is a unverified entry in our universe. The most established brand-forward platform in the category.
Programs and pricing, in plain sentences
tirzepatide (injection) — status: unverified. $199-349 by tier reported; strongest insurance pathway for branded Zepbound
Every figure above carries its status — operator claims come from the provider, reported from third parties we cite, verified only after our own checkout walk. Machine-readable version: providers.json.
Update — August 14, 2026: Verified at its cited source: the April 2026 tirzepatide.us.com comparison lists Ro at $329/mo ("premium tier with concierge"), matching the top of our reported band. The insurance machinery remains the real product.
Verification status and open items
Current status: unverified, last touched 2026-08-14. Open verification items: dispensing pharmacy identity, state coverage map, cancellation terms. Source on file: tirzepatide.us.com. Corrections land within 48 hours via the public log — if your checkout contradicts this page, that report changes the dataset.
How Ro fits the market
The most established brand-forward platform in the category. Ro's real edge isn't its cash tiers ($199–349 reported) — it's the insurance machinery: coverage checks and prior-authorization support for branded Zepbound that no compounded-first operator matches. If commercial coverage is even possible for you, Ro's coverage check is the highest-value fifteen minutes in this market. Head-to-head: Ro vs NexLife. Where it lands overall: the price ladder, the category winners, and the program finder all compute from the same dataset this page renders.
Advertising disclosure: outbound provider links may be commission-bearing; our partner relationship with NexLife is disclosed on the ownership page and never alters statuses or rankings.